丙型病毒性肝炎抗病毒治疗的研究进展  

Progress and prospect of hepatitis C virus antivirals therapy

作　　者：刘菲菲[1] 龚作炯[1] 

机构地区：[1]武汉大学人民医院感染病科,430060

出　　处：《疑难病杂志》2017年第3期306-310,共5页Chinese Journal of Difficult and Complicated Cases

摘　　要：干扰素联合利巴韦林是治疗丙型病毒性肝炎的一线推荐,但干扰素联合利巴韦林治疗方案对一部分患者为禁忌,且对基因1型、经治、肝硬化的患者疗效差,甚至患者常因不良反应而停药。2011年,直接抗病毒药物的出现使不同基因型、初治、经治、肝硬化及干扰素禁忌证的患者可以达到较好的疗效,甚至可达到100%的持续病毒学应答(SVR),该文对丙型病毒性肝炎的治疗研究进展作一综述。Interferon plus ribavirin is recommended for the treatment of hepatitis c.But the interferon plus ribavirin treatment for some patients is taboo.Interferon plus ribavirin treatment for genotype 1,previously treated,and for liver cirrhosis patients with poor effects,even some patients often stopped because of side effects.After 2011 years,the DAAs can achieve good curative effect in different genotypes,untreated,previously treated,cirrhosis of the live,and interferon contraindications HCV patients,even can achieve 100%of SVR.The treatment of hepatitis C has good prospects.

关 键 词：丙型病毒性肝炎 抗病毒 干扰素 直接抗病毒药物 

分 类 号：R512.63[医药卫生—内科学]